--- title: A One-Time Experimental Treatment Might Control Cholesterol for Life description: If the treatment continues to work in further studies, a gene therapy in development could eliminate the need for daily pills or regular injections. canonical: https://time.com/article/2026/05/28/one-time-treatment-might-control-cholesterol/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2026-05-28T14:00:25.000Z article:modified_time: 2026-05-28T16:48:36.112Z article:section: Health og:title: A One-Time Experimental Treatment Might Control Cholesterol for Life og:description: If it continues to work in further studies, a gene therapy in development could eliminate the need for daily pills or regular injections. og:url: https://time.com/article/2026/05/28/one-time-treatment-might-control-cholesterol/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt4f60f1c2608a99cd/6a17a365c98f000c13bc1a94/GettyImages-2251352197.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 2272 og:image:height: 1278 og:image:alt: GettyImages-2251352197.jpg og:type: article twitter:card: summary_large_image twitter:title: A One-Time Experimental Treatment Might Control Cholesterol for Life twitter:description: If it continues to work in further studies, a gene therapy in development could eliminate the need for daily pills or regular injections. twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt4f60f1c2608a99cd/6a17a365c98f000c13bc1a94/GettyImages-2251352197.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # A One-Time Experimental Treatment Might Control Cholesterol for Life > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=1946a415-197d-4341-8f08-4c308aec3f3a&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | | Health Matters | The latest health news and expert advice on living well | Daily | | Worth Your Time | A weekly guide to what to watch, read, and more | Tuesday and Saturday (2x per week) | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Monday to Saturday (3x per week) | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | Source: TIME, August 2026. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=1946a415-197d-4341-8f08-4c308aec3f3a&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=1946a415-197d-4341-8f08-4c308aec3f3a&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (daily health), Worth Your Time (culture, twice weekly), D.C. Brief (Washington politics, three times a week), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement.  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent May 28, 2026 2:00 PM UTC  Ruslanas Baranauskas/Science Photo Library—Getty Images  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent May 28, 2026 2:00 PM UTC Heart disease[ kills more people worldwide](https://pmc.ncbi.nlm.nih.gov/articles/PMC10809869/) than any other malady, and even though [doctors use cholesterol-lowering medications and recommend lifestyle habits to control major risk factors](https://time.com/article/2026/04/13/heart-disease-is-preventable-sadiya-khan-essay/). Making these changes, however, is not easy for people, and sticking with them is even harder. The hope is that one day soon, people may not have to rely solely on these interventions. In a study conducted by Verve Therapeutics, which is owned by Eli Lilly Co., and published May 25 in the[ New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2601283?query=featured%5Fhome), researchers report some encouraging news about a one-time gene therapy that could control [cholesterol](https://time.com/6209652/how-to-lower-your-cholesterol-naturally/), one of the prime contributors to [heart disease](https://time.com/tag/heart-disease/). Among the 35 people who participated in the study, the gene therapy reduced [LDL cholesterol](https://time.com/6287926/cholesterol-myths-debunked/) by anywhere from 9% to 62%, depending on the dose they received. The therapy targets a gene called PCSK9\. About 20 years ago,[ researchers at UT Southwestern Medical Center](https://pmc.ncbi.nlm.nih.gov/articles/PMC3991204/) found that people with mutations in their PCSK9 gene tended to have very low levels of LDL, and therefore low rates of heart events. PCSK9 works in the liver to regulate cholesterol, and it turns out that these people had an inactive form of the gene that led to lower levels of cholesterol in the blood, without any other apparent physiological effects. Scientists went to work developing drugs to inhibit the gene, and there are currently four such drugs approved for lowering cholesterol. But all of them are injectable medications; one requires a doctor to administer. The inconvenience of the injections means that about 30-50% of people stop using the drugs after about a year, and the drop-off rate is similar to that for daily [statin](https://time.com/6250225/statins-risks-cholesterol/) pills. The gene therapy, called VERVE-102, is meant to address that compliance problem with a one-time treatment to edit genes in liver cells so they continuously produce the changed version of PCSK9 that leads to low cholesterol. The alteration generated by the therapy doesn’t cause the exact change in the PCSK9 gene found in those born with the low-cholesterol version of the gene, but the end result is the same: the gene is inactivated, and LDL levels drop. “\[This study\] is early clinical evidence that we can give protection to people who weren’t born with it,” says Dr. Sek Kathiresan, senior vice president at Eli Lilly Co. and CEO of Verve Therapeutics. “We still have a lot to learn. But if it holds up, we think it would mean an entirely new way to treat high cholesterol with one infusion for lifelong cholesterol-lowering.” If it proves safe and effective in later clinical trials and eventually gets approved, the gene therapy could replace regular injections or daily pills because the liver cells that the therapy targets turn over every 200 to 300 days. Once the cells have been edited by VERVE-102, they produce more cells with the same genetic change, therefore sustaining the effect of the altered PCSK9—potentially over a lifetime. So far, the patients in the study have been followed for about 18 months and continue to show low LDL levels. Kathiresan says studies in animals show they continue to have low LDL levels after three years, which makes the scientists confident that the treatment is durable. The only side effect of note is that the drug temporarily causes higher levels of a liver enzyme, says Kathiresan, reflecting the fact that the gene therapy targets liver cells and initially may disrupt levels of liver compounds. The current trial included people either with a genetic predisposition to high cholesterol or who had early heart events, but Lilly plans to conduct a larger trial of about 200 people—including more people in the latter category who might be more representative of those who have heart disease. The company will also continue to follow the 35 people in this first trial for 15 years to monitor the safety of the gene therapy they received. For safety reasons, people in the current study also continued taking cholesterol-lowering medications, including statins, during the trial. But future research will address whether at some point, a one-time gene therapy like VERVE-102 could replace statins altogether. “It’s too early to say right now, and a lot will depend on where people start in terms of their cholesterol and where their goal is,” says Kathiresan. “But ultimately, we would love to be in a position where this is the preferred therapy of choice.” ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/article/2026/05/28/one-time-treatment-might-control-cholesterol/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/article/2026/05/28/one-time-treatment-might-control-cholesterol/"},"headline":"A One-Time Experimental Treatment Might Control Cholesterol for Life","datePublished":"2026-05-28T14:00:25.000Z","dateModified":"2026-05-28T16:48:36.112Z","description":"If it continues to work in further studies, a gene therapy in development could eliminate the need for daily pills or regular injections.","url":"https://time.com/article/2026/05/28/one-time-treatment-might-control-cholesterol/","keywords":["Heart Disease"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt4f60f1c2608a99cd/6a17a365c98f000c13bc1a94/GettyImages-2251352197.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt4f60f1c2608a99cd/6a17a365c98f000c13bc1a94/GettyImages-2251352197.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"GettyImages-2251352197.jpg","caption":"","creditText":"Ruslanas Baranauskas/Science Photo Library—Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/heart-disease/","name":"Heart Disease"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/article/2026/05/28/one-time-treatment-might-control-cholesterol/","name":"A One-Time Experimental Treatment Might Control Cholesterol for Life"}}]}] ```